A potent and selective PHOX2B promoter-driven oncolytic adenovirus for targeted neuroblastoma therapy
Open Access
- 24 June 2026
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 201, 119710
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science
This publication has 37 references indexed in Scilit:
- Oncolytic virus and immunogenic cell death in cancer therapyTumour Virus Research, 2025
- DAMPs in the immunogenicity of cell deathMolecular Cell, 2025
- Oncolytic Virotherapy in Solid Tumors: A Current ReviewBioDrugs, 2025
- Viral and non-viral vectors in gene therapy: current state and clinical perspectivesEBioMedicine, 2025
- DAMPs and DAMP-sensing receptors in inflammation and diseasesImmunity, 2024
- Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cellsTranslational Oncology, 2021
- Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicineGenes & Diseases, 2017
- RIPK1 and RIPK3: critical regulators of inflammation and cell deathTrends in Cell Biology, 2015
- Transcriptional dysregulation and impairment of PHOX2B auto-regulatory mechanism induced by polyalanine expansion mutations associated with congenital central hypoventilation syndromeNeurobiology of Disease, 2013
- Molecular cloning and characterization of the promoter region of the human Phox2b geneMolecular Brain Research, 2004